Journal
CLINICAL AND MOLECULAR HEPATOLOGY
Volume 27, Issue 1, Pages 1-21Publisher
KOREAN ASSOC STUDY LIVER
DOI: 10.3350/cmh.2020.0028
Keywords
Anti-mitochondrial antibody; Epidemiology; Bezafibrate
Categories
Funding
- Health and Labor Sciences Research Grant
Ask authors/readers for more resources
Primary biliary cholangitis (PBC) is an autoimmune disease that mainly affects middle-aged women but also young women and men. It is characterized by degeneration and necrosis of intrahepatic biliary epithelial cells, with early diagnosis through detection of antimitochondrial antibodies and introduction of ursodeoxycholic acid as first-line treatment significantly improving clinical outcomes.
Primary biliary cholangitis (PBC) causes chronic and persistent cholestasis in the liver, eventually resulting in cirrhosis and hepatic failure without appropriate treatment. PBC mainly develops in middle-aged women, but it is also common in young women and men. PBC is considered a model of autoimmune disease because of the presence of disease-specific autoantibodies, that is, antimitochondrial antibodies (AMAs), intense infiltration of mononuclear cells into the bile ducts, and a high prevalence of autoimmune diseases such as comorbidities. Histologically, PBC is characterized by degeneration and necrosis of intrahepatic biliary epithelial cells surrounded by a dense infiltration of mononuclear cells, coined as chronic non-suppurative destructive cholangitis, which leads to destructive changes and the disappearance of small- or medium-sized bile ducts. Since 1990, early diagnosis with the detection of AMAs and introduction of ursodeoxycholic acid as first-line treatment has greatly altered the clinical course of PBC, and liver transplantation-free survival of patients with PBC is now comparable to that of the general population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available